Ke Li

Kunming, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Structural basis of the AlgU-MucAcyto interaction and SspB-mediated degradation in Pseudomonas aeruginosa stress response.

Structural basis of the AlgU-MucAcyto interaction and SspB-mediated degradation in Pseudomonas aeruginosa stress response.

Journal: mBio

Published: May 19, 2026

Unmasking the "targetless" illusion: branched clonal evolution of TERT and KIT in acral melanoma revealed by sequential multi-site biopsies- a case report.

Unmasking the "targetless" illusion: branched clonal evolution of TERT and KIT in acral melanoma revealed by sequential multi-site biopsies- a case report.

Journal: Frontiers in immunology

Published: February 13, 2026

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Journal: JAMA oncology

Published: January 02, 2026

Identification and validation of prognostic genes and prognostic models associated with cutaneous melanoma and integrative stress response.

Identification and validation of prognostic genes and prognostic models associated with cutaneous melanoma and integrative stress response.

Journal: Frontiers in immunology

Published: August 20, 2025

Enhanced homing and efficacy of HER2-CAR T cells via CXCR5/CCR6 co-expression for HER2-positive NSCLC.

Enhanced homing and efficacy of HER2-CAR T cells via CXCR5/CCR6 co-expression for HER2-positive NSCLC.

Journal: Journal of translational medicine

Published: May 03, 2025

Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAFV600-mutant advanced melanoma: a multicenter cohort study.

Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAFV600-mutant advanced melanoma: a multicenter cohort study.

Journal: MedComm

Published: June 11, 2024

Transformed Giant Congenital Melanocytic Nevus on 18 F-FDG PET/CT.

Transformed Giant Congenital Melanocytic Nevus on 18 F-FDG PET/CT.

Journal: Clinical nuclear medicine

Published: July 24, 2023

HNRNPA2B1-mediated m6A modification of lncRNA MEG3 facilitates tumorigenesis and metastasis of non-small cell lung cancer by regulating miR-21-5p/PTEN axis.

HNRNPA2B1-mediated m6A modification of lncRNA MEG3 facilitates tumorigenesis and metastasis of non-small cell lung cancer by regulating miR-21-5p/PTEN axis.

Journal: Journal of translational medicine

Published: February 24, 2023

The role of artificial intelligence based on PET/CT radiomics in NSCLC: Disease management, opportunities, and challenges.

The role of artificial intelligence based on PET/CT radiomics in NSCLC: Disease management, opportunities, and challenges.

Journal: Frontiers in oncology

Published: December 28, 2022

Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis.

Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis.

Journal: Journal of the American Academy of Dermatology

Published: June 19, 2022

PPP1R14D promotes the proliferation, migration and invasion of lung adenocarcinoma via the PKCα/BRAF/MEK/ERK signaling pathway.

PPP1R14D promotes the proliferation, migration and invasion of lung adenocarcinoma via the PKCα/BRAF/MEK/ERK signaling pathway.

Journal: International journal of oncology

Published: June 06, 2022

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.

Journal: Frontiers in immunology

Published: February 08, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026